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Background
Liver fibrosis and cirrhosis are late complications com-
mon to liver diseases of different etiology such as viral
hepatitis and alcoholic liver disease. Irrespective of the
initial cause of liver disease, activation of hepatic stellate
cells is a crucial step in the fibrotic pathomechanism. Acti-
vated hepatic stellate cells produce excess collagen as well
as profibrotic cytokines and change to a contractile phe-
notype which reduces the diameter of the hepatic sinu-
soids. Activation of hepatic stellate cells is reduced by an
increase in intracellular cyclic guanosine monophoshate
(cGMP). Stable cGMP analogues also reduce the contrac-
tile response of hepatic stellate cells. However, cGMP pro-
duction is downregulated in the cirrhotic liver due to
reduced activity of the endothelial NO synthase. The
recently discovered activators of soluble guanylate cyclase
(sGC) increase cGMP production independently of NO.
We therefore investigated the effects of an sGC activator in
two classical rat models of liver fibrosis, the pig serum
model and the carbon tetrachloride model.
Material and Methods
Liver fibrosis was induced by i. p. administration of sterile
pig serum (twice weekly) or oral administration of car-
bontetrachloride (every fifth day), respectively in female
Sprague Dawley rats. Ths sGC activator was administered
at doses of 0.1 and 0.3 mg/kg p.o. daily concomitantly to
the fibrotic stimulus. After 7 weeks the rat were sacrificed
and liver fibrosis was assessed both morphometrically by
Sirius Red staining of fibrous collagen and by hydroxypro-
line determination.
Results
Both fibrotic stimuli resulted in a massive increase in
hepatic collagen compared to healthy controls. In the
serum model concomitant treatment with 0.1 mg/kg p.o.
of the sGC activator was sufficient to reduce this increase
by about 75%. A reduction of hepatic fibrosis by about
60% was achieved with 0.3 mg/kg p.o. in the carbon tet-
rachloride model.
Conclusion
Activation of soluble guanylate cyclase prevented hepatic
collagen accumulation both in inflammatory and non-
inflammatory models of liver fibrosis. sGC activators
might thus provide a new antifibrotic principle for liver
diseases of different etiology.
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